CHMP Recommends EU Approval of Roche PGx Drug Zelboraf
December 21, 2011
CHMP Recommends EU Approval of Roche PGx Drug Zelboraf
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- PGx Highlights from the American Society of Clinical Oncology's 2012 Meeting
June 14, 2012 / Pharmacogenomics Reporter - Pfizer, Roche Officials Share Lessons Learned from Rx/Dx Co-development of Xalkori and Zelboraf
February 29, 2012 / Pharmacogenomics Reporter - Quest Study Finds Sanger-based BRAF Mutation Test More Sensitive than Roche's Cobas Test
June 13, 2012 / Pharmacogenomics Reporter - ASCO Presentations on PGx Melanoma Drugs Portend Crowded Market for BRAF-Mutated Tumors
June 6, 2012 / Pharmacogenomics Reporter - Thomas Jefferson University Hospital Offering Roche's FDA-Approved BRAF Test
November 9, 2011 / Pharmacogenomics Reporter